Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

SHE:300204 Revenue

Staidson (Beijing) BioPharmaceuticals had revenue of 46.90M CNY in the quarter ending March 31, 2026, a decrease of -25.81%. This brings the company's revenue in the last twelve months to 203.92M, down -30.42% year-over-year. In the year 2025, Staidson (Beijing) BioPharmaceuticals had annual revenue of 220.23M, down -32.20%.

• Revenue (ttm): 203.92M
• Revenue Growth: -30.42%
• P/S Ratio: 60.40
• Revenue / Employee: 415.31K
• Employees: 484
• Market Cap: 12.32B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	220.23M	-104.58M	-32.20%
Dec 31, 2024	324.82M	-39.36M	-10.81%
Dec 31, 2023	364.18M	-184.81M	-33.66%
Jan 1, 2023	548.99M	-35.30M	-6.04%
Dec 31, 2021	584.29M	159.08M	37.41%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 30, 2026

Data Sources Report a data error